Cargando…

Metabolomic disorders: confirmed presence of potentially treatable abnormalities in patients with treatment refractory depression and suicidal behavior

BACKGROUND: Refractory depression is a devastating condition with significant morbidity, mortality, and societal cost. Approximately 15% of patients with major depressive disorder are refractory to currently available treatments. We hypothesized metabolic abnormalities contributing to treatment refr...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Lisa A., Segreti, Anna Maria, Wrobleski, Joseph, Shaw, Annie, Hyland, Keith, Hughes, Marion, Finegold, David N., Naviaux, Robert K., Brent, David A., Vockley, Jerry, Peters, David G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520591/
https://www.ncbi.nlm.nih.gov/pubmed/36330595
http://dx.doi.org/10.1017/S0033291722003233
_version_ 1785109954418442240
author Pan, Lisa A.
Segreti, Anna Maria
Wrobleski, Joseph
Shaw, Annie
Hyland, Keith
Hughes, Marion
Finegold, David N.
Naviaux, Robert K.
Brent, David A.
Vockley, Jerry
Peters, David G.
author_facet Pan, Lisa A.
Segreti, Anna Maria
Wrobleski, Joseph
Shaw, Annie
Hyland, Keith
Hughes, Marion
Finegold, David N.
Naviaux, Robert K.
Brent, David A.
Vockley, Jerry
Peters, David G.
author_sort Pan, Lisa A.
collection PubMed
description BACKGROUND: Refractory depression is a devastating condition with significant morbidity, mortality, and societal cost. Approximately 15% of patients with major depressive disorder are refractory to currently available treatments. We hypothesized metabolic abnormalities contributing to treatment refractory depression are associated with distinct findings identifiable in the cerebrospinal fluid (CSF). Our hypothesis was confirmed by a previous small case-controlled study. Here we present a second, larger replication study. METHODS: We conducted a case-controlled, targeted, metabolomic evaluation of 141 adolescent and adult patients with well-characterized history of depression refractory to three maximum-dose, adequate-duration medication treatments, and 36 healthy controls. Plasma, urine, and CSF metabolic profiling were performed by coupled gas chromatography/mass spectrometry, and high-performance liquid chromatography, electrospray ionization, tandem mass spectrometry. RESULTS: Abnormalities were identified in 67 of 141 treatment refractory depression participants. The CSF abnormalities included: low cerebral folate (n = 20), low tetrahydrobiopterin intermediates (n = 11), and borderline low-tetrahydrobiopterin intermediates (n = 20). Serum abnormalities included abnormal acylcarnitine profile (n = 12) and abnormal serum amino acids (n = 20). Eighteen patients presented with two or more abnormal metabolic findings. Sixteen patients with cerebral folate deficiency and seven with low tetrahydrobiopterin intermediates in CSF showed improvement in depression symptom inventories after treatment with folinic acid and sapropterin, respectively. No healthy controls had a metabolite abnormality. CONCLUSIONS: Examination of metabolic disorders in treatment refractory depression identified an unexpectedly large proportion of patients with potentially treatable abnormalities. The etiology of these abnormalities and their potential roles in pathogenesis remain to be determined.
format Online
Article
Text
id pubmed-10520591
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-105205912023-09-27 Metabolomic disorders: confirmed presence of potentially treatable abnormalities in patients with treatment refractory depression and suicidal behavior Pan, Lisa A. Segreti, Anna Maria Wrobleski, Joseph Shaw, Annie Hyland, Keith Hughes, Marion Finegold, David N. Naviaux, Robert K. Brent, David A. Vockley, Jerry Peters, David G. Psychol Med Original Article BACKGROUND: Refractory depression is a devastating condition with significant morbidity, mortality, and societal cost. Approximately 15% of patients with major depressive disorder are refractory to currently available treatments. We hypothesized metabolic abnormalities contributing to treatment refractory depression are associated with distinct findings identifiable in the cerebrospinal fluid (CSF). Our hypothesis was confirmed by a previous small case-controlled study. Here we present a second, larger replication study. METHODS: We conducted a case-controlled, targeted, metabolomic evaluation of 141 adolescent and adult patients with well-characterized history of depression refractory to three maximum-dose, adequate-duration medication treatments, and 36 healthy controls. Plasma, urine, and CSF metabolic profiling were performed by coupled gas chromatography/mass spectrometry, and high-performance liquid chromatography, electrospray ionization, tandem mass spectrometry. RESULTS: Abnormalities were identified in 67 of 141 treatment refractory depression participants. The CSF abnormalities included: low cerebral folate (n = 20), low tetrahydrobiopterin intermediates (n = 11), and borderline low-tetrahydrobiopterin intermediates (n = 20). Serum abnormalities included abnormal acylcarnitine profile (n = 12) and abnormal serum amino acids (n = 20). Eighteen patients presented with two or more abnormal metabolic findings. Sixteen patients with cerebral folate deficiency and seven with low tetrahydrobiopterin intermediates in CSF showed improvement in depression symptom inventories after treatment with folinic acid and sapropterin, respectively. No healthy controls had a metabolite abnormality. CONCLUSIONS: Examination of metabolic disorders in treatment refractory depression identified an unexpectedly large proportion of patients with potentially treatable abnormalities. The etiology of these abnormalities and their potential roles in pathogenesis remain to be determined. Cambridge University Press 2023-10 2022-11-04 /pmc/articles/PMC10520591/ /pubmed/36330595 http://dx.doi.org/10.1017/S0033291722003233 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
spellingShingle Original Article
Pan, Lisa A.
Segreti, Anna Maria
Wrobleski, Joseph
Shaw, Annie
Hyland, Keith
Hughes, Marion
Finegold, David N.
Naviaux, Robert K.
Brent, David A.
Vockley, Jerry
Peters, David G.
Metabolomic disorders: confirmed presence of potentially treatable abnormalities in patients with treatment refractory depression and suicidal behavior
title Metabolomic disorders: confirmed presence of potentially treatable abnormalities in patients with treatment refractory depression and suicidal behavior
title_full Metabolomic disorders: confirmed presence of potentially treatable abnormalities in patients with treatment refractory depression and suicidal behavior
title_fullStr Metabolomic disorders: confirmed presence of potentially treatable abnormalities in patients with treatment refractory depression and suicidal behavior
title_full_unstemmed Metabolomic disorders: confirmed presence of potentially treatable abnormalities in patients with treatment refractory depression and suicidal behavior
title_short Metabolomic disorders: confirmed presence of potentially treatable abnormalities in patients with treatment refractory depression and suicidal behavior
title_sort metabolomic disorders: confirmed presence of potentially treatable abnormalities in patients with treatment refractory depression and suicidal behavior
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520591/
https://www.ncbi.nlm.nih.gov/pubmed/36330595
http://dx.doi.org/10.1017/S0033291722003233
work_keys_str_mv AT panlisaa metabolomicdisordersconfirmedpresenceofpotentiallytreatableabnormalitiesinpatientswithtreatmentrefractorydepressionandsuicidalbehavior
AT segretiannamaria metabolomicdisordersconfirmedpresenceofpotentiallytreatableabnormalitiesinpatientswithtreatmentrefractorydepressionandsuicidalbehavior
AT wrobleskijoseph metabolomicdisordersconfirmedpresenceofpotentiallytreatableabnormalitiesinpatientswithtreatmentrefractorydepressionandsuicidalbehavior
AT shawannie metabolomicdisordersconfirmedpresenceofpotentiallytreatableabnormalitiesinpatientswithtreatmentrefractorydepressionandsuicidalbehavior
AT hylandkeith metabolomicdisordersconfirmedpresenceofpotentiallytreatableabnormalitiesinpatientswithtreatmentrefractorydepressionandsuicidalbehavior
AT hughesmarion metabolomicdisordersconfirmedpresenceofpotentiallytreatableabnormalitiesinpatientswithtreatmentrefractorydepressionandsuicidalbehavior
AT finegolddavidn metabolomicdisordersconfirmedpresenceofpotentiallytreatableabnormalitiesinpatientswithtreatmentrefractorydepressionandsuicidalbehavior
AT naviauxrobertk metabolomicdisordersconfirmedpresenceofpotentiallytreatableabnormalitiesinpatientswithtreatmentrefractorydepressionandsuicidalbehavior
AT brentdavida metabolomicdisordersconfirmedpresenceofpotentiallytreatableabnormalitiesinpatientswithtreatmentrefractorydepressionandsuicidalbehavior
AT vockleyjerry metabolomicdisordersconfirmedpresenceofpotentiallytreatableabnormalitiesinpatientswithtreatmentrefractorydepressionandsuicidalbehavior
AT petersdavidg metabolomicdisordersconfirmedpresenceofpotentiallytreatableabnormalitiesinpatientswithtreatmentrefractorydepressionandsuicidalbehavior